Hims & Hers shares plunge 28% on concerns over weight loss business, margins
Hims & Hers on Monday released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...
Hims & Hers Health, Inc. (HIMS): Jim Cramer Weighs in on This Digital Health Stock
We recently published a list of Jim Cramer Discusses These 12 Stocks & Trump DOJ’s Action Against Health Insurance Companies.
Hims is officially phasing out its copycat weight-loss drugs, and the company's stock tumbled — again
After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop making copies.
Hosted on MSN12m
Hims & Hers Stock Is Plunging on Weight-Loss Drug Halt. Should You Buy the Dip?
Shares of the leading health and wellness platform Hims & Hers (HIMS) are under pressure following the company’s ...
STAT43m
Lilly expands its Zepbound vial offering, as Hims pulls back on semaglutide
Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...
NBC2627m
Hims and Hers likely to stop selling cheaper versions of GLP-1 medications
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded versions due to regulatory changes.
Eli Lilly cuts price of weight-loss drug Zepbound as competition heats up
Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will also ...